Top Markets
#1 Pleasing Gold Pleasing Gold +1,463.64%
#2 PulseChain PulseChain +59.45%
#3 BOOK OF MEME BOOK OF MEME +34.33%
#4 Merlin's Seal BTC Merlin's Seal BTC +32.88%
#5 Ontology Gas Ontology Gas +28.49%
#6 Unit Pump Unit Pump +24.72%
#7 Pump.fun Pump.fun +24.72%
#8 Nockchain Nockchain +22.61%
#9 Neiro Neiro +21.92%
#10 ConstitutionDAO ConstitutionDAO +20.25%
Coin of the day
Pleasing Gold Pleasing Gold
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Abnova (Taiwan) Corporation Abnova (Taiwan) Corporation

Abnova (Taiwan) Corporation

4133
Rangering i aksjer #26492
Abnova (Taiwan) Corporation specializes in the development and distribution of... Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.
Aksjekurs
$0.66300973
Markedsverdi
$40.15M
Endring (1 dag)
1.46%
Endring (1 år)
-20.61%
Land
TW
Handel Abnova (Taiwan) Corporation (4133)

Kategori

Healthcare
P/E-forhold for Abnova (Taiwan) Corporation (4133)
P/E-forhold per 2026 TTM: 0
Ifølge Abnova (Taiwan) Corporation sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Abnova (Taiwan) Corporation fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.